Lymphomatoid papulosis--treatment with recombinant interferon alfa-2a and etretinate.
Lymphomatoid papulosis is a rare cutaneous lymphoproliferative disorder with nodular, papulonecrotic or plaque-like lesions. Although it is clinically benign, the histology shows large, atypical lymphoid cells that display antigenic markers of activated T-helper lymphocytes and express CD30. There is a close relationship to Hodgkin's disease and to Ki-1-positive anaplastic large-cell lymphoma of the skin. For therapy, various modalities such as PUVA, steroids and acyclovir have been used. We report on a patient with a 10-year history of disease. Treatment with interferon alfa-2a, 3 MU 3 times/week for 4 weeks, and etretinate, 50 mg/day for 5 months, was initially successful, but lesions further relapsed 5 months after cessation of the therapy.
Wyss
M
M
Department of Dermatology, University Hospital Zurich, Switzerland.
Dummer
R
R
Dommann
S N
SN
Joller-Jemelka
H I
HI
Dours-Zimmermann
M T
MT
Gilliet
F
F
Burg
G
G
D000328:Adult; D001706:Biopsy; D003131:Combined Modality Therapy; D005050:Etretinate / Q000627:therapeutic use*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D017731:Lymphomatoid Papulosis / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D008297:Male; D011994:Recombinant Proteins; D012867:Skin / Q000473:pathology
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D005050:Etretinate